The Series C round of funding will be used to establish Regentis's European presence and expand its ongoing clinical effort of GelrinC, the biodegradable implant that enhances articular cartilage growth in damaged knee joints. It's currently an investigational device and not available for sale in the United States, Europe or Israel.
GelrinC fits tightly within surrounding cartilage and underlying bone to closely restore cartilage to the pre-injury condition. Regentis is currently conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of the device.
More Articles on Orthopedic Devices:
Internal Fixation Systems Enters Into Agreement With Intelligent Orthopaedics for Trauma Device
U.S. Orthopedic Biomaterials Market Poised for Growth
TranS1 Q1 Revenue Plummets 26%
a
Regentis Biomaterials Raises $10M for Knee Cartilage Regeneration Implant
Written by Laura Miller | May 14, 2012
Regentis Biomaterials, a company focused on developing proprietary hydrogels for tissue regeneration, has raised $10 million in its latest round of funding from new investors Royal DSM through its venturing subsidiary, Crossroad Fund, Medica Venture Partners, SCPVitalife and Technion Investment Opportunities Fund.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.